We report the first-in-human safety and immunogenicity evaluation of PENNVAX-G DNA/modified vaccinia Ankara-Chiang Mai double recombinant (MVA-CMDR) prime-boost human immuonodeficiency virus (HIV) vaccine, with intramuscular DNA delivery by either Biojector 2000 needle-free injection system (Biojector) or CELLECTRA electroporation device.
by modified vaccinia Ankara-Chiang Mai double recombinant (MVA-CMDR) in healthy HIV-uninfected adults in the United States and East Africa. This study represents the first-in-human experience of PVG DNA delivered by either method and of the PVG DNA/MVA-CMDR prime-boost combination. It is also the first direct comparison of HIV DNA administration by electroporation or needle-free injection device.
METHODS

Participants and Study Design
The study was a multicenter, randomized trial to evaluate safety and immunogenicity of a prime-boost regimen of 4 mg of PVG DNA delivered intramuscularly by needle-free injection or electroporation at baseline (week 0) and 4 weeks, followed by intramuscular injection of 10 8 plaque-forming units of MVA-CMDR at 12 and 24 weeks (Supplementary Table 1 ). The open-label part A was conducted in Rockville, Maryland. Safety evaluation of part A was performed before initiation of part B, which was placebo controlled and conducted in Kampala, Uganda; Kericho, Kenya; and Mbeya, Tanzania. Study participants were healthy, at low risk of HIV acquisition, and had normal baseline electrocardiograms. The protocol was approved by institutional and ethical review boards at the Walter Reed Army Institute of Research, Kenya Medical Research Institute, Tanzanian National Institute of Medical Research, and Ugandan National HIV/AIDS Research Committee. Written informed consent was obtained from each participant. The study was registered at ClinicalTrials. gov (NCT01260727). All vaccines were administered in the deltoid muscle. Except for the assessment of immediate pain, reactogenicity was assessed at 45 minutes, 6 hours, and then daily for 6 days after injection. Adverse events were recorded at all study visits from baseline to study completion. After screening, laboratory monitoring included routine hematology, chemistry, and creatine phosphokinase measured at weeks 0, 2, 6, 12, 14, 24, 26, 37 , and 50, with troponin I measured 2 weeks after each MVA/ placebo injection. Immunogenicity assessments were performed on cryopreserved specimens collected at baseline and at weeks 6, 14, 26, and 50. All participants provided phlebotomy specimens for ELISpot and binding antibody evaluations; a subset were selected for additional evaluation by intracellular cytokine staining (ICS), neutralizing antibody (NAb), and antibody-dependent cell-mediated cytotoxicity (ADCC) assays. Participants were given the option of participating in a mucosal substudy that collected semen and cervico-vaginal mucus for quantification of binding antibodies. Cervico-vaginal mucus was collected using the Instead Softcup (The Flex Company, Venice, CA).
Vaccine Product and Delivery
PENNVAX-G is a mixture of 4 DNA plasmids that encode consensus HIV immunogens selected to develop an internationally relevant DNA vaccine. Plasmids pEY1E1 (pGX1001), pEY3E1 (pGX1002), and pEY4E1 (pGX1004) encode consensus Env (gp140) immunogens for HIV subtypes A, C, and D, respectively [29, 30] . Plasmid pMC-Gag (pGX1005) encodes a multiclade (subtypes A, B, C, and D) consensus Gag immuonogen. All 4 plasmids use the modified pVAX1 expression vector [24] (pGX0001) with changes only to the HIV sequences inserted into the gene expression cassette. Participants were randomized to intramuscular PVG administration by either the Biojector 2000 Needle Free Injection System (formerly Biojector, Inc, Bedminster, NJ; presently Inovio Pharmaceuticals, Plymouth Meeting, PA) or the CELLECTRA electroporation device (Inovio Pharmaceuticals). The Biojector 2000 uses sterile, single-use syringes that deliver the study material using a compressed carbon dioxide cartridge. The CELLECTRA electroporation device delivers 3 pulses at 0.5 A constant current, with a 52-millisecond pulse length and a 1-second rest between pulses following injection of the DNA by needle and syringe via a hand-held applicator [23, 31] .
Modified vaccinia Ankara-Chiang Mai double recombinant is a recombinant, live-attenuated modified vaccinia virus-vectored vaccine genetically engineered to express HIV-1 gp150 (CRF01_AE, isolate CM235) and Gag and Pol (integrase-deleted and nonfunctional reverse transcriptase, subtype A, isolate CM240) [32, 33] . The MVA-CMDR was delivered intramuscularly by needle and syringe.
Immunogenicity
ELISpot
Interferon γ (IFN-γ) ELISpot responses were measured to vaccine-matched Env, Gag, and Pol expression products (Supplementary Table 2 ) at baseline, week 6, and week 26 [5, 34] . Ninety-six-well hydrophobic membrane-bottom plates (Millipore, Billerica, MA) were coated overnight at 4°C with antihuman IFN-γ monoclonal antibody (MAb; Mabtech, Nacka Strand, Sweden). A panel of vaccine insert-matched Env, Gag, and Pol peptide pools was used to stimulate 2 × 10 5 peripheral blood mononuclear cells (PBMCs) per well overnight at 37°C in 5% carbon dioxide. Captured IFN-γ was incubated with a biotinylated antihuman IFN-γ MAb (Mabtech), and peroxidase staining was performed using 3-amino-9-ethylcarbazole substrate (Vectastain AEC Kit, Vector Laboratories, Burlingame, CA). Results are expressed as spot-forming cells (SFCs) per 10 6 PBMCs. A positive IFN-γ response was defined as ≥55 SFCs per 10 6 PBMCs (uncorrected) and at least 4 times the average of the dimethyl sulfoxide-treated wells.
Intracellular Cytokine Staining
Among vaccine recipients with available specimen, 29 ELISpot responders and 9 nonresponders were selected for additional characterization by qualified intracellular cytokine staining for IFN-γ at weeks 0, 14, and 26 [16] . Cells were stimulated with vaccine-matched peptide pools for CMDR Env and CMDR Gag (1 μg/mL for each peptide), with positive control phorbol myristate acetate (PMA, 1μg/mL) and ionomycin (1μg/mL), or with dimethyl sulfoxide containing media alone. Stimulations were performed in the presence of CD107a PE-Cy7 (clone H4A3), CD154 PE-Cy5 (clone TRAP-1), and the costimulatory molecules CD28/CD49d MAbs (Becton Dickenson, San Jose, CA) for 4 hours. Following stimulation, cells were stained with Aqua Live/Dead, followed by surface staining with MAbs for CD14 (clone M5E2), CD19 (clone HIB19), and CD56 clone HCD56-all BV510-and CD4-BV605 (clone RPA-T4). Peripheral blood mononuclear cells were permeabilized and stained intracellularly with MAbs against IFN-γ-eFluor450 (clone 4S.B3) and CD8-PerCp efluor 710 (clone SK1), TNF-α-FITC (clone MAb11), CD3-APC-H7 (clone SK7), IL-4-APC (clone MP4-25D2), and IL-2-PE (clone MQ1-17H12). Cells were acquired on an FACS LSRII SORP cytometer (Becton Dickenson) and analyzed using Flow Jo (TreeStar, Inc, Ashland, OR). A median 110 000 (range, 16 668-209 000) CD3 + lymphocytes were acquired. A positive response was defined by a 2-fold increase over the unstimulated condition and a frequency >0.025% of CD8 or CD4 T cells. The criteria for positivity was not validated but used to increase sensitivity for this assay.
Binding Antibody
Recombinant gp120 CRF01_AE A244 and scaffold gp70 V1V2 Env protein (subtype B case A2 and CRF01_AE 92TH023) antigens were expressed and purified [35] [36] [37] . Plasma enzymelinked immunosorbent assay binding antibody (bAb) endpoint titers were performed [35] . Antibody titers were determined at weeks 0, 6, 14, 26, and 50. Antibody titers were calculated as a reciprocal plasma dilution using serial 2-fold dilutions and expressed as end-point titers; geometric mean titers (GMTs) were calculated from end-point titers.
Neutralizing Antibody
Neutralizing antibody responses were measured in a subset of participants comprised of 10 of 13 participants from part A and roughly half of the participants from part B (n = 20/42 in Uganda, n = 12/22 in Kenya, and n = 12/23 in Tanzania). Participants were selected equally from different administration routes with preferential inclusion of those with high binding antibody titers. Serum was evaluated at weeks 0, 26, and 50. The TZMbl pseudovirus neutralizing assay was performed at a screening serum dilution of 1:20 [38] , using a panel of 6 tier 1 pseudoviruses encoding HIV-1 Env genes, including BaL (subtype B), GS015 (subtype C), A03349M1 (subtype D), 271 (CRF02_AG), TH023 (CRF01_AE) and CM235 (CRF01_AE), as well as a pseudovirus expressing the murine leukemia virus Env as a negative control. Neutralization using PBMCs as target cells was also conducted using replication-competent Renilla reniformis luciferase (LucR)-expressing HIV-1 infectious molecular clones encoding HIV-1 Env genes, including CM235, TH023, SF162 (subtype B), and GS015 [39] . All sera were titered to achieve a 50% inhibitory dose in the PBMC/LucR infectious molecular clone assay.
Antibody-Dependent Cell-Mediated Cytotoxicity
Antibody-dependent cell-mediated cytotoxicity responses were measured to the subtype B MN protein and to the CRF01_AE CM235 protein at weeks 0, 6, 26, and 50 in participants with available specimen. The ADCC activity was measured by flow cytometry using a rapid fluorometric ADCC assay [40] . The CEM-NKr T lymphoblast cell line expressing CCR5 was labeled with the intracellular dye CFSE and the membrane dye PKH26 and then pulsed with gp120 proteins (5 µg/mL). Healthy donor PBMCs and plasma from the vaccinated participants were added to the labeled CEM-NKr cells for 6 hours. The cell mix was fixed, and the proportion of cells that maintained membrane expression of PKH26 but lost intracellular CFSE (PKH26 + CFSE − ) was analyzed by flow cytometry. Data are displayed as percentage of lysed target cells (%PKH26 + CFSE − ) at a plasma dilution of 1:1000. The cutoff for positivity was defined by the average of the antigen-pulsed PKH26 + CFSE − CEM-NKr target cells incubated with normal human serum.
Statistical Analysis
All analyses combined part A and part B study participants. Safety analyses are based on the intent-to-treat principle and include all participants in the group to which they were randomized. For the presentation of reactogenicity data, number and percentage of participants reporting each type of sign or symptom were tabulated by severity and study group. Each participant's reactogenicity is reported once under the maximum severity for all injection visits, and differences between groups were assessed using Fisher's exact test. ELISpot responses are presented as responder frequency to individual and cumulative peptide pools across tested visits. Intracellular cytokine staining, binding antibody, neutralizing antibody, and ADCC responses are plotted by DNA delivery device and week number, with week 0 representing baseline values. Flow cytometry analysis and presentation of distributions were performed using SPICE version 5-1.2, downloaded from http://exon.niaid.nih.gov/ spice [41] . Comparison of distributions was performed using a Student's t test and a partial permutation test [41] . All other group comparisons were made using nonparametric tests and SAS (Cary, NC) or GraphPad PRISM (La Jolla, CA) software.
RESULTS
Among the 100 participants enrolled, the median age was 27 years (range, 18-48 years) and 24 (24%) were female. Of 13 part A participants in the United States, 10 (77%) were nonwhite; all part B participants were African (Table 1) . Thirteen participants were enrolled in part A, and 11 completed all injections. Eighty-seven participants were enrolled in part B (n = 42 in Uganda, n = 22 in Kenya, and n = 23 in Tanzania), and 77 completed all injections. Forty-four male participants contributed semen, and 11 female participants provided cervico-vaginal mucus specimens. Reasons for study discontinuation are detailed in Figure 1 and included 1 pregnancy and 1 HIV infection following the second DNA vaccination.
Safety and Tolerability
Immunizations were safe and well tolerated. There were no study pauses or study-related serious adverse events. There were no discontinuations due to study-related adverse events. Reactogenicity was predominantly mild to moderate (Figure 2 ). Grade 3 episodes included an isolated fever of 40.1°C 6 hours after the 4th vaccination, headache on day 3 after the 3rd vaccination, and warmth at the injection site 6 hours after the 2nd vaccination. Immediate pain at the injection site was reported as moderate or severe by 4% (n = 2/51) of Biojector recipients compared with 51% (n = 25/49) of electroporation recipients (P < .0001), and local swelling was also more common in electroporation recipients (P = .03). There were no differences among groups in experiencing local pain or systemic reactogenicity at subsequent timepoints. Study-related adverse events in vaccine recipients were mild or moderate, the latter comprised of epistaxis (n = 1), neutropenia (n = 1), and tonsillitis (n = 1) that were classified as possibly related.
Immunogenicity
ELISpot
Peripheral blood mononuclear cells from Uganda, Kenya, and the United States were included in the IFN-γ ELISpot analysis, whereas PBMCs from Tanzania were excluded from cellular immunogenicity analyses due to high background activation. Table 3 ). There were no significant differences between DNA delivery methods in number of responders or in response magnitude. All reactions except immediate pain were assessed at 45 minutes, 6 hours, and then daily for 6 days after injection. P values shown are for Fisher's exact test for differences between electroporation and Biojector followed by differences between active vaccine and placebo recipients. Abbreviations: A, active vaccine; BJ, Biojector; EP, electroporation; P, placebo. Figure 3A) . Cumulative Env-specific CD4 T-cell responses developed in 32 of 38 (84%) recipients (Supplementary Table 4 ). CD8 T-cell IFN-γ responses against HIV-1 CMDR Env were observed, albeit at a lower frequency, in 23 of 38 (61%) participants tested ( Figure 3A) . CMDR Gagspecific CD4 and CD8 T-cell IFN-γ cumulative responses were demonstrated in 23 of 38 (61%) and 10 of 38 (26%) vaccine recipients, respectively ( Figure 3B and Supplementary Table 4) . Functional responses ( Figure 3C and D) for HIV-1 Env-specific CD4 T cells included TNF-α (>50%) expression by the majority of cells. Other CD4 T-cell responses were distributed among those that expressed IFN-γ, IL-4, IL-2, and CD107a. The majority of Env-specific T cells were monofunctional, expressing only TNF-α, CD107a, or IL-4. The HIV-1 Env-specific CD8 T-cell responses were dominated by those expressing either TNF-α or CD107a; combinations of functions were rarely observed. There were no differences in the number of responders, magnitude of the response, or polyfunctionality between the electroporation and Biojector groups.
BJ-A BJ-P EP-P EP-A BJ-A BJ-P EP-P EP-A BJ-A BJ-P EP-P EP-A BJ-A BJ-P EP-P EP-A BJ-A BJ-P EP-P EP-A BJ-A BJ-P EP-P EP-A BJ-A BJ-P EP-P EP-A BJ-A BJ-P EP-P EP-A BJ-A BJ-P EP-P EP-A BJ-A BJ-P EP-P EP-A BJ-A BJ-P EP-P EP-A BJ-A BJ-P EP-P EP-
BJ-P EP-P EP-A BJ-A BJ-P EP-P EP-A BJ-A BJ-P EP-P EP-A BJ-A BJ-P EP-P EP-A BJ-A BJ-P EP-P EP-A BJ-A BJ-P EP-P EP-
PENNVAX-G
Binding Antibody
Binding antibody responses were minimal after DNA administration and peaked after the 2nd MVA injection (Figure 4 ). All vaccinated participants had bAb responses to gp120 A244 at week 26 with GMTs of 1120 and 872 for Biojector and electroporation recipients, respectively, and those responses declined significantly by week 50. Geometric mean titers (141 vs 88; P = .02) and response rates (66% vs 33%; P = .01) to A244 gp120 were higher in the Biojector group compared with the electroporation group at week 50 ( Figure 4A ). Responses to gp70 V1V2 (92TH023) scaffold were demonstrated in 100% of Biojector and 97% of electroporation recipients at week 26 with GMTs of 639 and 566, respectively ( Figure 4B ). V1V2 antibody responses also declined in both groups by week 50, with no differences between Biojector and electroporation delivery ( Figure 4B ). Antibodies to gp70 V1V2 subtype B case A2 scaffold were weak and were only detected in 3 US participants at peak immunogenicity (data not shown). Furthermore, no bAb responses were detected in cervico-vaginal mucus or seminal plasma at the lowest dilution tested (1:25; data not shown).
Neutralizing Antibody
TZMbl screening neutralization assays were negative for all participants tested against 6 tier 1 pseudoviruses, including CM235 (data not shown). The PBMC neutralization assay using the CRF01_AE CM235 LucR infectious molecular clone detected neutralization in 84% (n = 43/51) of participants at week 26 in both the Biojector and electroporation groups ( Figure 5A) ; prevaccination sera were negative in this assay. Neutralization activity observed at week 26 was shown to be antibody mediated and partially NK-cell dependent. Titers were reduced to baseline when immunoglobulin G was depleted from the serum (Supplementary Figure 1A) , and neutralization activity was reduced when NK cells were depleted from the PBMC target population (Supplementary Figure 1B) . Participants with the highest titers to CM235 (n = 10 in the Biojector group and n = 6 in the electroporation group) were further evaluated using additional LucR infectious molecular clones at week 26. The subtype C GS015 and CRF01_AE TH023 infectious molecular clones were neutralized by sera from all 16 participants evaluated, whereas minimal neutralization was observed with the subtype B SF162 infectious molecular clone ( Figure 5B ). Statistical differences were not observed between immunization routes.
Antibody-Dependent Cell-Mediated Cytotoxicity
No ADCC activity was detected in the placebo recipients at any time point tested or in evaluated vaccine recipients at baseline. There was no CRF01_AE CM235-specific ADCC activity detected in vaccine recipients at week 6, whereas at week 26, 12 of 29 (41%) Biojector recipients and 19 of 36 (53%) electroporation recipients showed ADCC activity, respectively ( Figure 6A ). The median magnitude of PKH26 + CFSE− CEM-NKr target cells among responders was 26.7% and 19.4% for Biojector and electroporation administration of PENNVAX-G DNA, respectively (P = .02, Mann-Whitney test). Antibody-dependent cell-mediated cytotoxicity activity against CM235 correlated with neutralization activity demonstrated in the PBMC assay (P = .002) (Supplementary Figure 1C) . In contrast, the B.MN_ D11_gD−specific ADCC response, which is not matched to the vaccine insert, was less frequent at week 26 with 4 of 29 (14%) in the Biojector and 3 of 36 (8%) in the electroporation group displaying a positive response ( Figure 6B ).
DISCUSSION
The PVG/MVA-CMDR prime-boost regimen was generally safe and well tolerated across DNA delivery methods. We observed minimal reactogenicity, with systemic symptoms occurring at a rate similar to placebo. Participants in the electroporation arm reported significantly more local swelling and pain, but difference in local pain was restricted to the short time immediately after product administration and resolved quickly, consistent with previous observations [31] . Local pain measured at the diary time points was not significantly different between DNA delivery methods. We did not observe cardiac symptoms nor evidence of myo/pericarditis, adding to the growing body of literature documenting the cardiac safety of MVA-vectored HIV vaccines [42] . As seen in other DNA/MVA prime-boost HIV vaccines, the PENNVAX-G DNA/MVA-CMDR regimen induced T-cell responses in the majority of vaccine recipients, including CD4 and CD8 responses. However, in this study, they were both primarily directed towards Env. Gag-specific ICS responses were less robust than those observed in early phase trials of other DNA/MVA HIV vaccines [12, 14, 15] . The nature of the HIV Env-specific CD4 T-cell response in this study was more monofunctional and included higher levels of CD107a-producing cells compared with a study of MVA-CMDR administration alone [16] . CD4 responses expressing CD40L, IL-2, and IL-4, which were associated with decreased risk of HIV infection in RV144 [43] , were not frequently observed. There were high numbers of baseline responders measured by ICS (up to 39%). The high level of baseline activity could be reflective of less stringent criteria for positivity, compared with a more common 3 times background and a frequency >0.05% of CD4 or CD8 T cells [16, 44] , or may represent potential cross-reactivity of peptides in the peptide pools.
In the RV144 trial, V1V2 scaffold binding antibody responses were a correlate of decreased risk for HIV acquisition [5, 45] . Therefore, it is intriguing that recipients of the PVG/MVA-CMDR regimen had frequent responses to V1V2 scaffold as well as to gp120, particularly for CRF01_AE antigens. Further, gp120 responses were higher and more frequent at study conclusion in the Biojector group, suggesting improved durability for that particular response with DNA delivery by needle-free injection. However, bAb responses were generally low in titer and NAb responses were not detectable in the TZMbl assay. Responses were detectable in the PBMC neutralization assay, both to homologous and cross-subtype heterologous infectious molecular clones. Neutralizing activity in the PBMC assay may reflect NK cell effector function (Supplementary Figure 1B) [39] . Indeed, PBMC NAb results correlated with observed ADCC responses, which were moderate and highest to vaccine-homologous antigen (Supplementary Figure 1C) . For enhanced humoral responses, subsequent prime-boost regimens may benefit from the addition of a protein component.
Because this study lacked an MVA-only arm, we are unable to demonstrate the independent contribution of the DNA prime to post-boost immune responses. However, we can observe that, across cellular and humoral immunogenicity measures, there was no appreciable advantage of electroporation over needle-free device delivery of the DNA prime for this PVG DNA/MVA-CMDR . Antibody-dependent cell-mediated cytotoxicity (ADCC). Magnitude of ADCC response in vaccine recipients was measured using gp120-coated targets labeled with PKH26 and CFSE at weeks 0, 6, 26, and 50. The frequency of lysed cells was defined by the loss of CFSE and retention of PKH26, resulting in the emergence of a "killed" PKH26 + CSFE − population. Antibody-dependent cell-mediated cytotoxicity response using gp120-coated target cells with CRF01_A/E (CM235) (A) and subtype B (MN) (B) were used, with the threshold for positive responses at 11.5% and 17.2%, respectively. Vaccination timepoints are indicated with an arrow. Data are plotted by DNA immunization route, electroporation (black) or biojector (red). Response rates were not significantly different between DNA delivery groups.
regimen. Although not directly comparable, this is consistent with data from the TaMoVac02 Trial, which evaluated a DNA/MVA-CMDR approach with or without protein boost and demonstrated no augmentation of immune responses with intradermal electroporation (Derma Vax) when it was added to intradermal DNA delivery by needle-free jet injection [46] . In the HVTN 070/080 studies evaluating the role of electroporation delivery and interleukin 12 adjuvant with PENNVAX-B DNA, a third DNA vaccine dose was important for induction of HIV-specific cellular responses [23] . Additional evaluation is warranted to assess the role of the DNA prime, optimize additional delivery parameters and number of DNA vaccinations, and determine if a protein component in the regimen, either as a boost or coadministered with DNA priming, can improve the magnitude and functional characteristics of the vaccine-elicited immune response.
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